Tevogen Bio Holdings (TVGN)
NASDAQ:TVGN
Want to see TVGN full AI Analyst Report?
TVGN Stock Chart & Stats
$0.32
-$0.17(-11.18%)
At close: 4:00 PM EST
$0.32
-$0.17(-11.18%)
Day’s Range― - ―
52-Week Range$4.14 - $75.50
Previous CloseN/A
Volume2.03M
Average Volume (3M)557.82K
Market Cap
$26.82M
Enterprise Value$29.37M
Total Cash (Recent Filing)$552.37K
Total Debt (Recent Filing)$3.10M
Price to Earnings (P/E)―
Beta1.00
Next Earnings
Jun 03, 2026Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.50
Shares Outstanding4,164,205
10 Day Avg. Volume531,944
30 Day Avg. Volume557,817
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)-6.68
Price to Sales (P/S)0.00
P/FCF Ratio-4.44
Enterprise Value/Market Cap1.10
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-57.67
Enterprise Value/Ebitda-1.15
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)-9.5
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Nasdaq Listing Compliance RegainedRegaining Nasdaq compliance via the reverse split materially reduces near-term delisting risk and preserves access to a regulated trading venue. That sustained listing status supports future capital-raising options and market visibility, which are durable enablers for financing clinical development.
Debt Reduction In 2024–2025A meaningful reduction in debt across 2024–2025 eases solvency pressure and lowers fixed obligations. This structural improvement strengthens financial flexibility and extends runway, reducing refinancing risk and allowing management to prioritize R&D investment over debt service.
Specialized T‑cell Immunotherapy FocusConcentrating on precision T‑lymphocyte therapies targets high unmet medical need and benefits from high scientific barriers to entry. This niche offers potential durable competitive advantages if clinical progress continues, as expertise, IP, and manufacturing know‑how are persistent moat elements in cell therapy.
Bears Say
No Commercial RevenueAbsence of product revenue over multiple years indicates the company remains pre‑commercial and wholly reliant on external financing. Without demonstrated sales or commercialization, future cash needs and execution risk remain elevated, making operational and funding sustainability uncertain.
Consistent Negative Cash FlowSustained negative operating and free cash flow show ongoing cash burn that mirrors net losses, depleting liquidity absent financing. This persistent outflow creates structural dependency on capital markets or dilution, constraining long‑term planning and making development timelines contingent on successful funding.
Negative Stockholders' EquityAn entrenched equity deficit reflects accumulated losses and weakens the balance sheet, limiting borrowing capacity and strategic flexibility. Negative equity can impede certain financing alternatives and increases sensitivity to adverse events, representing a durable solvency and governance concern.
Tevogen Bio Holdings News
TVGN FAQ
What was Tevogen Bio Holdings’s price range in the past 12 months?
Tevogen Bio Holdings lowest stock price was $4.13 and its highest was $75.50 in the past 12 months.
What is Tevogen Bio Holdings’s market cap?
Tevogen Bio Holdings’s market cap is $26.82M.
When is Tevogen Bio Holdings’s upcoming earnings report date?
Tevogen Bio Holdings’s upcoming earnings report date is Jun 03, 2026 which is in 48 days.
How were Tevogen Bio Holdings’s earnings last quarter?
Tevogen Bio Holdings released its earnings results on Nov 14, 2025. The company reported -$1.5 earnings per share for the quarter, beating the consensus estimate of -$3.04 by $1.54.
Is Tevogen Bio Holdings overvalued?
According to Wall Street analysts Tevogen Bio Holdings’s price is currently Overvalued.
Does Tevogen Bio Holdings pay dividends?
Tevogen Bio Holdings does not currently pay dividends.
What is Tevogen Bio Holdings’s EPS estimate?
Tevogen Bio Holdings’s EPS estimate is -2.
How many shares outstanding does Tevogen Bio Holdings have?
Tevogen Bio Holdings has 4,164,205 shares outstanding.
What happened to Tevogen Bio Holdings’s price movement after its last earnings report?
Tevogen Bio Holdings reported an EPS of -$1.5 in its last earnings report, beating expectations of -$3.04. Following the earnings report the stock price went down -6.122%.
Which hedge fund is a major shareholder of Tevogen Bio Holdings?
Currently, no hedge funds are holding shares in TVGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Tevogen Bio Holdings
Tevogen Bio Holdings Inc. operates as a clinical-stage biotechnology company that develops off-the-shelf precision T cell therapeutics in virology, oncology, and neurology. Its lead investigational precision T cell product, TVGN 489, is designed to address the unmet need of acute-risk COVID-19 patients, as well as a subset of patients suffering from long COVID. The company is based in Warren, New Jersey.
TVGN Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Nkarta
―
C4 Therapeutics
―
Shattuck Labs
―
Nuvectis Pharma
―
Actuate Therapeutics, Inc.
―